# Peter Sinnaeve

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-sinnaeve/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,956 |
| Field | Coronary Interventions and Diagnostics |
| h-index | 55 |
| i10-index | 136 |
| Last Known Institution | Çevre, Şehircilik ve İklim Değişikliği Bakanlığı |
| OpenAlex ID | https://openalex.org/A5038384001 |
| ORCID iD | https://orcid.org/0000-0003-4716-5892 |
| Works | 394 |

## Researcher papers

- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non/)
- [Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-interleukin-1-inhibition-with-canakinumab-on-incident-lung-cancer-in/)
- [Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation](https://scholariq.org/papers/antithrombotic-therapy-after-acute-coronary-syndrome-or-pci-in-atrial/)
- [2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation](https://scholariq.org/papers/2021-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin/)
- [Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial](https://scholariq.org/papers/relationship-of-c-reactive-protein-reduction-to-cardiovascular-event-reduction/)
- [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](https://scholariq.org/papers/effects-of-alirocumab-on-cardiovascular-and-metabolic-outcomes-after-acute/)
- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non-2/)

## Researcher topics

- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Çevre, Şehircilik ve İklim Değişikliği Bakanlığı](https://scholariq.org/institutions/cevre-sehircilik-ve-iklim-degisikligi-bakanl-g/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.